During the corresponding time, Gossamer Bio Inc saw a revenue deteriorated by -19.59 % year on year, sequentially revenue fell by -45.51 %. While revenue at the Gossamer Bio Inc 's corporate clients
Gossamer Bio Inc's Comment on Sales, Marketing and Customers
Third-party payors in the United States, including Medicare, have varying policies regarding coverage and reimbursement for seralutinib, which may impact its commercialization and financial returns. These payors increasingly evaluate the price, medical necessity, and cost-effectiveness of medical products. Legislative and regulatory changes, such as those introduced by the Affordable Care Act (ACA), seek to contain healthcare costs, improve quality, and expand access, potentially resulting in more stringent coverage criteria and downward pressure on drug prices.
In a move set to bolster its workforce and strengthen its ongoing research efforts, Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company, recently announced the Compensation Committee of its Board of Directors approved an inducement grant. Effective June 5, 2024, the grant includes a non-qualified stock option to a new non-executive employee, in compliance with Nasdaq Listing Rule 5635(c)(4).Gossamer Bio is at the forefront of developing innovative therapies targeting serious diseases, with a particular focus on pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Both PAH and PH-ILD are chronic, debilitating conditions ...
Gossamer Bio Announces Positive First Quarter 2024 Financial Results and Advances in Development of Seralutinib for Pulmonary Hypertension TreatmentSAN DIEGO - Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), has reported its financial results for the first quarter ended March 31, 2024. In addition, the company has provided an update on its business progress.Gossamer Bio continues to remain steadfast in its mission to enhance the lives of patients suffering from PAH and PH-ILD. The...
Pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) are debilitating conditions characterized by elevated blood pressure in the pulmonary arteries, leading to progressive heart failure and reduced life expectancy. Current treatment options for these conditions are limited, often providing only symptomatic relief and failing to address the underlying pathophysiology. However, a recent publication in the Lancet Respiratory Medicine journal sheds light on a potential game-changer in the field of pulmonary hypertension treatment - seralutinib.The TORREY Phase 2 study:Gossamer Bio, a leading clinical-stage biopharmaceutical company, has spearheaded t...
Gossamer Bio Inc’s Comment on Sales, Marketing and Customers
Third-party payors in the United States, including Medicare, have varying policies regarding coverage and reimbursement for seralutinib, which may impact its commercialization and financial returns. These payors increasingly evaluate the price, medical necessity, and cost-effectiveness of medical products. Legislative and regulatory changes, such as those introduced by the Affordable Care Act (ACA), seek to contain healthcare costs, improve quality, and expand access, potentially resulting in more stringent coverage criteria and downward pressure on drug prices.
Sources:
Gossamer Bio Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Gossamer Bio Inc’s corporate clients.
For your research, we’ve provided 9 tables on Gossamer Bio Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
283.54 %